Clene Inc.
CLNNDrugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
9dMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
CLNN Earnings Report
EPS Est: $-0.37 | FQ end 2026-06
How CLNN's past catalysts played out
CNM-Au8
Relapsing Multiple Sclerosis
CNMAu8
Amyotrophic Lateral Sclerosis
CNM-ZnAg
Covid19
gold nanocrystals
Multiple Sclerosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CNM-Au8 | Phase 3 | Relapsing Multiple Sclerosis | - | - |
CNMAu8 | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
CNM-ZnAg | Phase 2 | Covid19 | - | - |
gold nanocrystals | Phase 2 | Multiple Sclerosis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Clene Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Clene Inc.'s (CLNN) pipeline across Phase 3, Phase 2. Its lead program is CNM-Au8 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Clene Inc.'s next FDA catalyst?→
Clene Inc.'s (CLNN) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CLNN biotech catalysts?→
Add CLNN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Clene Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.